Mark Blumenkranz

Mark Blumenkranz

Director/Board Member presso KALA BIO, INC.

Patrimonio netto: 51 351 $ in data 31/03/2024

73 anni
Health Technology
Consumer Services
Finance

Profilo

Mark S.
Blumenkranz
, M.D., MMS, is HJ Smead Professor in the Department of Ophthalmology at Stanford University.
He received his Undergraduate, Masters degree in biochemical pharmacology, and MD at Brown, Ophthalmic residency training at Stanford, and a Fellowship in vitreo-retinal diseases at the Bascom Palmer Eye Institute.
? He was a director of Oculex Pharmaceuticals, a privately held pharmaceutical company that pioneered the use of bio-erodable polymers for extended release of ocular steroids.
At Oculex he was also Chairman of the SAB and the principal designer of the successful phase 2 Ozurdex trial, leading to its acquisition by Allergan in 2003.
He served as a co-founder, Director and Chairman of the SAB of Macusight, an ophthalmic pharmaceutical company developing proprietary mTor inhibitors for ophthalmic disease, which was acquired by Santen in 2010.
He was a founder and director of Peak Surgical, an innovator in pulsed plasma mediated electro-surgery that was acquired by Medtronics in 2011.
In 2004 he co-founded Optimedica Corporation for which he co-wrote the foundation IP for the PASCAL and Catalys lasers, and which was acquired by AMO in 2013.
In 2006 co-founded Adverum Biotechnologies (ADVM; NASDAQ) a gene therapy company and served as Chairman of the Board until 2016.
He was a co-founder and director of Oculeve, a dry eye company employing a neuro-modulatory approach to therapy, which was acquired by Allergan in August of 2015.
He is a co-founder and serves as a director of Digisight Corporation, a venture financed ophthalmic digital health company and Lagunita Biosciences LLC an early stage biotechnology and medical investment company.
?

Partecipazioni note in società pubbliche

SocietàDataNumero di azioniValorizzazioneData di valutazione
22/06/2023 6 443 ( 0.24% ) 51 351 $ 31/03/2024

Posizioni attive di Mark Blumenkranz

SocietàPosizioneInizio
KALA BIO, INC. Director/Board Member 15/11/2021
Oculogics, Inc. Director/Board Member -
Founder 01/10/2015
Director/Board Member 27/02/2019
Director/Board Member -
Stanford University Corporate Officer/Principal 01/01/1997
Combangio Corp. Director/Board Member -
Director/Board Member -
Consultant / Advisor -
░░░░░░░ ░░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
Tutte le posizioni attive di Mark Blumenkranz

Precedenti posizioni note di Mark Blumenkranz

SocietàPosizioneFine
░░░░░░ ░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░
░░░░░░░░░░ ░░░░ ░░░░░░░░ -
░░░░░░ ░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░░░░
Vedi nel dettaglio l'esperienza di Mark Blumenkranz

Formazione di Mark Blumenkranz

Brown University Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Mark Blumenkranz

Relazioni

100 +

Relazioni di 1° grado

35

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa3
KALA BIO, INC.

Health Technology

ADVERUM BIOTECHNOLOGIES, INC.

Health Technology

PRESBIA PLC

Health Technology

Aziende private29

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Services

Health Technology

Health Technology

Finance

Association of University Professors of Ophthalmology

Macula Society

Health Technology

The Retina Society

Midlab, Inc.

Health Technology

Commercial Services

Byers Eye Institute

Health Technology

Health Technology

Technology Services

Oculogics, Inc.

Health Technology

Finance

Health Technology

Health Technology

Retinal Degeneration Fund

Finance

Commercial Services

Combangio Corp.

Vedi le connessioni aziendali
  1. Borsa valori
  2. Insiders
  3. Mark Blumenkranz